PCSK1N and Parkinson disease: While SAAs hold promise for enhancing early PD detection, unravelling potential for a diagnosis at a preclinical stage beyond the capacity of traditional criteria, the clinical criteria's primary strength remains in diagnosing symptomatic rather than preclinical or prodromal cases.28